SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Curis Lifesciences Ltd

BSE: 0 NSE: CURIS ISIN: INE1BZN01016
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Curis Lifesciences Ltd belong to?
Curis Lifesciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Curis Lifesciences Ltd a good quality company?
Curis Lifesciences Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Curis Lifesciences Ltd undervalued or overvalued?
Curis Lifesciences Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Curis Lifesciences Ltd a good buy now?
Curis Lifesciences Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Curis Lifesciences Ltd?
Curis Lifesciences Ltd revenue growth is 38.2% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 18.2% for FY-2025 , which is above its 5 year median of 15.25% , indicating increasing margins.
Q.3 Operating Profit Margin of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 19.43% for FY-2025 , which is below its 5 year median of 19.52% indicating decreasing margins.
Q.4 Net Profit Margin of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Net Profit Margin is 12.43% for FY-2025 , is above with its 5 year median of 9.49%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 18.2 15.25
Operating Profit Margin 19.43 19.52
Net Profit Margin 12.43 9.49
Q.5 Return on Asset of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Return on Asset is 15.98%, which is above its 5 year historical median of 11.27%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Return on equity is 55.25% for FY-2025 , which is below its historical median of 1862.56%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Return on capital employed is 34.25% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Cash conversion cycle is 108 days, above its historical median of 64 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.29 1.21
ROE 55.25 1862.56
ROCE 34.25 30.59
Cash Conversion Cycle 108 days 64 days
Q.9 Debt to Equity ratio of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Debt-to-Equity ratio is 0.96 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Curis Lifesciences Ltd?
Curis Lifesciences Ltd Debt to cash flow from operations is -8.86 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Curis Lifesciences Ltd?
Promoters hold % of the Curis Lifesciences Ltd, with % of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Curis Lifesciences Ltd vs industry peers?
Curis Lifesciences Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 49.1 137.1
Gross Profit 8.9 15.1
Operating Profit 9.6 16
Net Profit 6.1 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.29 0.8
ROE 55.25 8.91
ROCE 34.25 11.59
Cash Conversion Cycle (days) 107.62 76

Valuation & price assessment

Q.1 Stock return of Curis Lifesciences Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -
Q.3 Valuation ratios of Curis Lifesciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 14.84 14.31 40.28
Price to Book 4.93 4.76 2.77
Price to Sales 1.84 1.78 2.65
EV to EBITDA 10.53 10.21 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×